Core Insights - Hologic (HOLX) is currently attractively priced with a Value Score of B, trading at a forward five-year price-to-sales (P/S) of 3.39X, which is lower than its median of 4.33X and the industry average of 4.14X [1][4] - The company has faced a tough macroeconomic environment, resulting in a 10.8% year-to-date decline in shares, underperforming the industry and S&P 500 [5] - Despite returning to top-line growth in Q3 of fiscal 2024, fiscal 2025 has shown mixed performance with a 0.9% revenue increase in Q1 and a 1.2% decline in Q2 [7][10] Valuation Comparison - Hologic's P/S ratio of 3.39X is favorable compared to peers QIAGEN (3.30X) and Abbott (2.50X), but it trades at a premium to the broader Medical sector's historical average of 2.33X [4] - The company has reaffirmed its revenue guidance but lowered its adjusted EPS forecast to $4.15-$4.25 from $4.25-$4.35, indicating potential challenges ahead [12] Performance Challenges - Hologic's performance has been impacted by a stronger U.S. dollar, a significant drop in Breast Health revenues, and the loss of a $50 million annual revenue stream from HIV testing in Africa [8][10] - Analysts have become increasingly cautious, with the Zacks Consensus Estimate for fiscal 2025 EPS decreasing by 2.1% to $4.19 over the past 90 days [13] Growth Drivers - The Surgical business has shown a 7.6% compound annual growth rate (CAGR) over the last decade, driven by products like MyoSure and the acquisition of Gynesonics [15] - Hologic's strong financial health is highlighted by $169.5 million in operating cash generated in Q2 of fiscal 2025 and a cash position of $1.43 billion [16] Overall Outlook - While Hologic's Surgical division shows ongoing momentum and financial stability, macroeconomic headwinds and declining sales in key areas have negatively impacted performance [17] - The negative earnings estimate trend suggests continued near-term challenges, leading to a less compelling investment case at this time [18]

Core Insights - Hologic (HOLX) reported a non-GAAP gross margin of 61.1% for Q2 of fiscal 2025, an increase of 40 basis points year-over-year, driven by strong diagnostic sales and high-margin acquisitions [1][8] - The company has adopted a cautious full-year outlook due to macroeconomic volatility, with expected tariff impacts adding $20 million-$25 million to quarterly costs [2] - Despite challenges, Hologic anticipates growth in its Diagnostics and Surgical segments, with gross margins projected to remain in the low 60s for the full year [3][8] Financial Performance - Hologic's operating margin for the quarter was 30%, which is among the strongest in its peer group, and increased by 60 basis points sequentially [1] - The Diagnostics segment is expected to grow in the mid-single digits, while the Surgical segment is projected to grow in the high-single digits [2][3] - The company has lowered its revenue forecast for China by approximately $20 million, now estimating $50 million, to mitigate geopolitical risks [2] Competitive Landscape - GE Healthcare (GEHC) reported an 80 basis points year-over-year improvement in adjusted gross margin, with an adjusted EBIT margin of 15% [4] - Bio-Rad (BIO) experienced a non-GAAP gross margin of 53.8%, down 0.7% year-over-year, but its operating margin increased to 10.8% [5] Stock Performance and Valuation - Hologic shares have decreased by 10.4% over the past six months, compared to a 13.8% decline in the industry [6] - The stock trades at a forward price-to-sales (P/S) ratio of 3.42X, which is above the sector average [9] - The Zacks Consensus Estimate for Hologic's fiscal 2025 earnings suggests a 2.9% year-over-year improvement [10]

Core Points - AKWEL has postponed its Annual General Meeting until after June 30, 2025, due to the ongoing finalization of the audit for the 2024 annual financial statements [2][3] - The company will file a request for postponement with the Commercial Court of Bourg-en-Bresse and will communicate the new schedule to the market as soon as possible [3] - The next press release regarding first-half 2025 sales is scheduled for July 24, 2025, after the close of trading [4] Company Overview - AKWEL is a systems supplier to the automotive and truck industries, specializing in fluid management, mechanisms, and structural parts for electric vehicles [2][4] - The company is independent and family-owned, listed on Euronext Paris, and employs approximately 8,600 people across 20 countries on five continents [4][5] - AKWEL possesses advanced industrial and technological expertise in the application and transformation of materials such as plastic, rubber, and metal, as well as in mechatronics integration [4]

Champfromier, Wednesday, May 28, 2025 PUBLICATION OF ANNUAL FINANCIAL REPORT ONCE AGAIN POSTPONED AKWEL (FR0000053027, AKW, PEA eligible), a systems supplier to the automotive and truck industries, specializing in fluid management, mechanisms and structural parts for electric vehicles, has once again postponed publication of its annual financial report by a few days. The request from the statutory auditors for further auditing of the control procedures implemented at the Ixtaczoquitlan site in Mexico has b ...

Company Overview - AKWEL is a systems supplier to the automotive and HGV industries, specializing in fluid management, mechanisms, and structural parts for electric vehicles [1][2] - The company is independent and family-owned, listed on Euronext Paris [2] - AKWEL operates in 20 countries across five continents and employs 8,600 people worldwide [3] Financial Reporting Update - The publication of AKWEL's annual financial report has been postponed until at least May 28, 2025, due to a request from statutory auditors for further auditing of control procedures at the Ixtaczoquitlan site in Mexico [1] - An internal audit conducted by the Group indicates that the results of the additional audit should not have a material impact on the financial statements [1] - The Annual General Meeting, originally scheduled for May 22, 2025, has been rescheduled to June 25, 2025 [1] Future Announcements - AKWEL plans to release sales figures for the first half of 2025 on July 24, 2025, after the close of trading [2]

Forward-Looking Statements Except for historical information contained herein, statements in this presentation are forward-looking statements that are made by Gentherm Incorporated (the "Company") pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements that address future operating, financial or business performance or strategies or expectations are forward-looking statements. The forward-looking statements included in this presentation are made as of t ...